Document:

EX. 4.27 Amendment - Tuchman

AMENDING AGREEMENT NO. 1
THIS AMENDING AGREEMENT made effective as of the 12th day of March, 2015.
BETWEEN:
ONCOYLYTICS BIOTECH (U.S.), INC.,
("OBUS")
- and -
ALAN J. TUCHMAN, M.D.
(the "Employee")
WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective September 27, 2012;
AND WHEREAS OBUS and the Employee wish to amend the Employment Agreement;
NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:
Section 1 – Amendments

The Employment Agreement is hereby amended by replacing Section 3(1) with the following:

“Commencing January 1, 2015, OBUS shall pay to the Employee a salary of ONE HUNDRED FORTY-SIX THOUSAND SIX HUNDRED SIXTY-NINE DOLLARS AND THIRTY-SEVEN CENTS ($146,669.37) U.S. DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of SIX THOUSAND ONE HUNDRED ELEVEN DOLLARS AND TWENTY-TWO CENTS ($6,111.22) U.S. DOLLARS on the 15th and last day of each month.”

   

Section 2 – Effective Date

(1)    This Amending Agreement shall be effective from and after January 1, 2015.

(2)    In all other respects the parties confirm that the Employment Agreement, as amended, shall remain in full force and effect.
	
				
	 
	 
	ONCOLYTICS BIOTECH (U.S.), INC.

	Per:
	/s/ Mary Ann Dillahunty

	 
	 
	 
	Mary Ann Dillahunty
President

	 
	 
	Per:
	/s/ Kirk Look

	 
	 
	 
	Kirk Look
Chief Financial Officer

	
			
	/s/ Margaret Kowalczewski
	 
	

/s/ Alan J. Tuchman

	WITNESS
	 
	ALAN J. TUCHMAN, M.D.EX. 4.28 Amendment - Dillahunty

AMENDING AGREEMENT NO. 1
THIS AMENDING AGREEMENT made effective as of the 12th day of March, 2015.
BETWEEN:
ONCOYLYTICS BIOTECH (U.S.), INC.,
("OBUS")
- and -
MARY ANN DILLAHUNTY
(the "Employee")
WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective January 22, 2009;
AND WHEREAS OBUS and the Employee wish to amend the Employment Agreement;
NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:
Section 1 – Amendments

The Employment Agreement is hereby amended by replacing Section 3(1) with the following:

“Commencing January 1, 2015, OBUS shall pay to the Employee a salary of ONE HUNDRED SIXTY-NINE THOUSAND THREE HUNDRED SEVENTY-ONE DOLLARS AND SEVENTY-THREE CENTS ($169,371.73) U.S. DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of FOURTEEN THOUSAND ONE HUNDRED FOURTEEN DOLLARS AND THIRY-ONE CENTS ($14,114.31) U.S. DOLLARS on the last day of each month.”

   

Section 2 – Effective Date

(1)    This Amending Agreement shall be effective from and after January 1, 2015.

(2)    In all other respects the parties confirm that the Employment Agreement, as amended, shall remain in full force and effect.
	
				
	 
	 
	ONCOLYTICS BIOTECH (U.S.), INC.

	Per:
	/s/ Alan J. Tuchman

	 
	 
	 
	Alan J. Tuchman, M.D.
Chief Medical Officer

	 
	 
	Per:
	/s/ Kirk Look

	 
	 
	 
	Kirk Look
Chief Financial Officer

	
			
	/s/ Margaret Kowalczewski
	 
	

/s/ Mary Ann Dillahunty

	WITNESS
	 
	MARY ANN DILLAHUNTYEX. 4.29 Amendment - Thompson

AMENDING AGREEMENT NO. 2
THIS AMENDING AGREEMENT made effective as of the 12th day of March, 2015.
BETWEEN:
ONCOYLYTICS BIOTECH INC.,
("ONCOLYTICS")
- and -
BRADLEY GEORGE THOMPSON,
(the "Employee")
WHEREAS the Employee is an officer of Oncolytics whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective January 1, 2013;
AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement;
NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:
Section 1 – Amendments

The Employment Agreement is hereby amended by replacing Section 3(1) with the following:

“Commencing January 1, 2015, Oncolytics shall pay to the Employee a salary of FIVE HUNDRED FIFTY-ONE THOUSAND NINE HUNDRED THIRTY-SIX DOLLARS AND SEVENTY CENTS ($551,936.70) CANADIAN per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of TWENTY-TWO THOUSAND NINE HUNDRED NINETY-SEVEN DOLLARS AND THIRTY-SIX CENTS  ($22,997.36) CANADIAN on the 15th and last day of each month.”

   

Section 2 – Effective Date

(1)    This Amending Agreement shall be effective from and after January 1, 2015.

(2)    In all other respects the parties confirm that the Employment Agreement, as amended, shall remain in full force and effect.
	
				
	 
	 
	ONCOLYTICS BIOTECH INC.

	Per:
	/s/ Matthew Coffey

	 
	 
	 
	Matthew Coffey, Ph.D.
Chief Operating Officer

	 
	 
	Per:
	/s/ Kirk Look

	 
	 
	 
	Kirk Look
Chief Financial Officer

	
			
	/s/ Margaret Kowalczewski
	 
	

/s/ Bradley Thompson

	WITNESS
	 
	BRADLEY G. THOMPSONEX. 4.30 Amendment - Gill

AMENDING AGREEMENT NO. 2
THIS AMENDING AGREEMENT made effective as of the 12th day of March, 2015.
BETWEEN:
ONCOYLYTICS BIOTECH (U.S.), INC.,
("OBUS")
- and -
GEORGE M. GILL, M.D.
(the "Employee")
WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective January 1, 2011;
AND WHEREAS OBUS and the Employee wish to amend the Employment Agreement;
NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:
Section 1 – Amendments

The Employment Agreement is hereby amended by replacing Section 3(1) with the following:

“Commencing January 1, 2015, OBUS shall pay to the Employee a salary of THREE HUNDRED SIXTEEN THOUSAND SEVEN HUNDRED FOURTY-TWO DOLLARS AND TWELVE CENTS ($316,742.12) U.S. DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of THIRTEEN THOUSAND ONE HUNDRED NINETY-SEVEN DOLLARS AND FIFTY-NINE CENTS ($13,197.59) U.S. DOLLARS on the 15th and last day of each month.”

   

Section 2 – Effective Date

(1)    This Amending Agreement shall be effective from and after January 1, 2015.

(2)    In all other respects the parties confirm that the Employment Agreement, as amended, shall remain in full force and effect.
	
				
	 
	 
	ONCOLYTICS BIOTECH (U.S.), INC.

	Per:
	/s/ Mary Ann Dillahunty

	 
	 
	 
	Mary Ann Dillahunty
President

	 
	 
	Per:
	/s/ Kirk Look

	 
	 
	 
	Kirk Look
Chief Financial Officer

	
			
	/s/ Margaret Kowalczewski
	 
	

/s/ George M. Gill

	WITNESS
	 
	GEORGE M. GILL, M.D.EX. 4.31 Amendment - Look

AMENDING AGREEMENT NO. 2
THIS AMENDING AGREEMENT made effective as of the 12th day of March, 2015.
BETWEEN:
ONCOYLYTICS BIOTECH INC.,
("ONCOLYTICS")
- and -
KIRK LOOK,
(the "Employee")
WHEREAS the Employee is an officer of Oncolytics whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective January 1, 2013;
AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement;
NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:
Section 1 – Amendments

The Employment Agreement is hereby amended by replacing Section 3(1) with the following:

“Commencing January 1, 2015, Oncolytics shall pay to the Employee a salary of  THREE HUNDRED NINETEEN THOUSAND TWO HUNDRED ($319,200.00) DOLLARS CANADIAN per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of THIRTEEN THOUSAND THREE HUNDRED  ($13,300.00) DOLLARS CANADIAN on the 15th and last day of each month.”

   

Section 2 – Effective Date

(1)    This Amending Agreement shall be effective from and after January 1, 2015.

(2)    In all other respects the parties confirm that the Employment Agreement, as amended, shall remain in full force and effect.
	
				
	 
	 
	ONCOLYTICS BIOTECH INC.

	Per:
	/s/ Brad Thompson

	 
	 
	 
	Brad Thompson, Ph.D.
Chief Executive Officer

	 
	 
	Per:
	/s/ Matthew Coffey

	 
	 
	 
	Matthew Coffey, Ph.D.
Chief Operating Officer

	
			
	/s/ Margaret Kowalczewski
	 
	

/s/ Kirk Look

	WITNESS
	 
	KIRK LOOKEX. 4.32 Amendment - Coffey

AMENDING AGREEMENT NO. 2
THIS AMENDING AGREEMENT made effective as of the 12th day of March, 2015.
BETWEEN:
ONCOYLYTICS BIOTECH INC.,
("ONCOLYTICS")
- and -
MATTHEW C. COFFEY,
(the "Employee")
WHEREAS the Employee is an officer of Oncolytics whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective January 1, 2013;
AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement;
NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:
Section 1 – Amendments

The Employment Agreement is hereby amended by replacing Section 3(1) with the following:

“Commencing January 1, 2015, Oncolytics shall pay to the Employee a salary of THREE HUNDRED EIGHTY THOUSAND ONE HUNDRED SEVEN DOLLARS AND THIRTY-FIVE CENTS ($380,107.35) CANADIAN per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of FIFTEEN THOUSAND EIGHT HUNDRED THIRTY-SEVEN DOLLARS AND EIGHTY ONE CENTS  ($15,837.81) CANADIAN on the 15th and last day of each month.”

   

Section 2 – Effective Date

(1)    This Amending Agreement shall be effective from and after January 1, 2015.

(2)    In all other respects the parties confirm that the Employment Agreement, as amended, shall remain in full force and effect.
	
				
	 
	 
	ONCOLYTICS BIOTECH INC.

	Per:
	/s/ Brad Thompson

	 
	 
	 
	Brad Thompson, Ph.D.
Chief Executive Officer

	 
	 
	Per:
	/s/ Kirk Look

	 
	 
	 
	Kirk Look
Chief Financial Officer

	
			
	/s/ Margaret Kowalczewski
	 
	/s/ Matthew C. Coffey

	WITNESS
	 
	MATTHEW C. COFFEY

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]